Evidence map›Paper›PMID 36140658›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Usefulness of Practitioner-Led Pancreatic Cancer Screening.

Kazuya Matsumoto, Yoshinori Kushiyama, Akio Izumi, Koji Ohnishi, Masahiko Miura, Yasufumi Ohuchi, Ikuko Hori, Tomonori Nakamura, Kotaro Hori, Kenji Koshino and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Kazuya MatsumotoIrisawa Medical Clinic, Matsue 690-0025, Japan.ORCID 0000-0002-5680-4791
Yoshinori KushiyamaPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Akio IzumiPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Koji OhnishiPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Masahiko MiuraPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Yasufumi OhuchiPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Ikuko HoriPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Tomonori NakamuraPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Kotaro HoriPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Kenji KoshinoPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Junko KobayashiPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Nagisa YoshinoPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Ushio HoshinoPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Takekiyo OkumuraPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Takashi TanimuraPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Shinsuke TanakaPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Shino TanakaPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Tadashi NabikaPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Tatsuaki NozuPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Yutaka WakatsukiPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Syunsuke KatayamaPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Shizue YoshiokaPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Kenichi ItoPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Akiko UchidaPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Noriji YuharaPancreatic Cancer Countermeasures Matsue Medical Association, Matsue 690-0048, Japan.
Hisashi NomaDepartment of Data Science, The Institute of Statistical Mathematics, Tachikawa 190-8562, Japan.ORCID 0000-0002-2520-9949
Hajime IsomotoDivision of Medicine and Clinical Science, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 5-year survival rate for pancreatic cancer has improved (10%) but remains worse than that for other cancers. Early pancreatic cancer diagnosis is challenging, and delayed diagnosis can delay treatment, which impairs survival. Practitioners do not promptly refer cases to a general hospital, causing delayed discovery. Herein, we aimed to examine the usefulness of the Pancreatic Cancer Project in Matsue, whose objective is to detect pancreatic cancer in patients presenting at any medical institution in Matsue City. Clinical data were extracted from medical records, and abdominal ultrasonography and tumor marker blood level assessments were performed (

Indexed as

abdominal ultrasoundcancer screeningpancreatic cancer

Identifiers

PMID36140658
PMCPMC9498137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.